Semnur Pharmaceuticals, Inc. (SMNR) Stock
SMNR has an Alpha Score of 19 out of 100 (poor), computed on Nov 8, 2026 from 2 of 4 sub-scores.
What is SMNR's Alpha Score?
How it works →Alpha Score of 19 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
What are SMNR's key statistics?
Key statistics as of Oct 31, 2026
SMNR price chart
Powered by TradingViewWhat does Semnur Pharmaceuticals, Inc. do?
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing innovative non-opioid pain management products for treating acute and chronic pain conditions. Its lead product candidate, SP-102, is a novel injectable corticosteroid gel formulation designed specifically for patients suffering from moderate to severe lumbosacral radicular pain, offering a targeted alternative to traditional opioid therapies. Headquartered in Palo Alto, California, and founded in 2013, the company operates with a small team of approximately two to three employees under CEO Jaisim Shah. Semnur Pharmaceuticals focuses exclusively on advancing its pipeline through clinical development stages, with no current revenue generation reported, reflecting its emphasis on research and potential regulatory approval. In the broader biopharmaceutical sector, Semnur plays a role in addressing the critical need for safer pain relief options amid the ongoing opioid crisis, positioning its candidates to impact treatments for neuropathic and radicular pain disorders. The company's efforts underscore a commitment to non-addictive solutions in a market increasingly prioritizing opioid-sparing innovations.